Gastric Cancer, Tumor Microenvironment, Immunotherapy, Chemotherapy
Conditions
Brief summary
The goal of this study is to analyze the tumor microenvironment (TME) in gastric cancer patients treated with combined immunotherapy and chemotherapy. The main questions it aims to answer are: * Provide profiles of TME between pre-treatment and post-treatment to gain insights into the mechanisms of immunotherapy combined with chemotherapy in advanced gastric cancer * Investigate the crucial factors affecting treatment efficacy by comparing gastric cancer patients with varying treatment responses
Interventions
S-1, Oxaliplatin and nivolumab/sintilimab
PROCEDUREGastroscopic biopsy
Gastroscopy and biopsy
Sponsors
Chinese PLA General Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Non-bedridden, aged 18 to 70 years old; * Eastern Cooperative Oncology Group (ECOG) score is 0 to 1; * Histologically confirmed gastric adenocarcinoma with evaluable lesions based on RECIST 1.1; * Advanced gastric cancer; * Ready for receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab
Exclusion criteria
* History of other malignant diseases in the last 5 years; * Prior chemotherapy, radiotherapy or immunotherapy; * Not receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Single-cell profiling | 6 months | Single-cell transcriptome and immune repertoire sequencing |
Countries
China
Contacts
Primary ContactXinxin Wang, MD
Outcome results
None listed